Posted: May 11th, 2022

Lung cancer treatment and success rates differ between genders

Lung cancer is a serious disease that affects millions of people worldwide. It is the leading cause of cancer-related deaths in both men and women. However, there are some differences in how lung cancer develops, progresses, and responds to treatment between genders. In this blog post, we will explore some of these differences and what they mean for patients and doctors.

Lung Cancer Incidence and Risk Factors

According to the American Cancer Society (ACS), lung cancer is more common in men than in women, but the gap is narrowing. In 2016, it was estimated that 117,920 men and 106,470 women would be diagnosed with lung cancer in the United States. However, the incidence of lung cancer in men has been declining since the 1980s, while the incidence in women has been increasing until recently.

One of the main reasons for this trend is smoking. Smoking is the most important risk factor for lung cancer, accounting for about 80% of cases. Men have historically smoked more than women, but women have been catching up in recent decades. Smoking also affects men and women differently. Some studies suggest that women are more susceptible to the carcinogens in cigarettes and develop lung cancer after fewer years of smoking than men. Other studies do not show an increased risk of lung cancer in women who smoke versus men who smoke.

Another interesting difference is that a greater percentage of women who develop lung cancer have never smoked. About 20% of lung cancer deaths in women occur in lifelong non-smokers, compared to only 1 in 12 men with lung cancer. The reasons for this are not clear, but some possible factors include exposure to secondhand smoke, radon gas, air pollution, or genetic mutations.

Lung Cancer Types and Stages

There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for about 80-85% of lung cancer cases and usually grows and spreads more slowly than SCLC. SCLC accounts for about 10-15% of lung cancer cases and is more aggressive and likely to spread quickly.

There are some differences in the distribution of these types between men and women. Women are more likely to have NSCLC than SCLC, especially adenocarcinoma, which is a subtype of NSCLC that often occurs in non-smokers or light smokers. Men are more likely to have SCLC or squamous cell carcinoma, which is another subtype of NSCLC that is associated with smoking.

Lung cancer is also classified by its stage, which indicates how far it has spread from its original site. The stages range from 0 to 4, with higher numbers indicating more advanced disease. Lung cancer stage is one of the most important factors that affect prognosis and treatment options.

Lung Cancer Survival Rates and Treatment Outcomes

Lung cancer survival rates are generally low compared to other cancers, but they vary depending on the type, stage, age, race, and sex of the patient. The ACS uses statistics from the Surveillance, Epidemiology, and End Results (SEER) database to calculate the 5-year relative survival rate of lung cancer. This rate compares a person with a specific type and stage of lung cancer to the general population to see how likely they are to live for 5 years after their initial diagnosis.

According to the SEER data, the overall 5-year relative survival rate for lung cancer is about 21%. However, this rate varies significantly by type and stage. For NSCLC, the 5-year relative survival rate is 65% for localized disease (cancer that has not spread beyond the lung), 37% for regional disease (cancer that has spread to nearby lymph nodes or tissues), and 9% for distant disease (cancer that has spread to other organs). For SCLC, the 5-year relative survival rate is 30% for localized disease, 18% for regional disease, and 3% for distant disease.

There are also differences in survival rates between men and women with lung cancer. Women tend to have better survival rates than men at all stages of the disease. This survival advantage over men is greatest for local disease, where surgical treatment of lung cancer offers a greater chance for a cure in women than in men. Some possible explanations for this difference include hormonal factors, genetic factors, immune system factors, or differences in tumor biology or response to therapy.

Lung cancer treatment options depend on several factors, such as the type, stage, location, size, and molecular characteristics of the tumor; the overall health and preferences of the patient; and the availability and effectiveness of different therapies. The main types of treatment for lung cancer include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of these. Some of these treatments may have different effects or side effects in men and women.

For example, some studies have shown that women may benefit more from certain targeted therapies, such as gefitinib or erlotinib, which are drugs that block the epidermal growth factor receptor (EGFR) that is often mutated in lung cancer cells. Women are more likely to have EGFR mutations than men, especially in adenocarcinoma and non-smoking patients. However, other studies have not found a significant difference in response to these drugs between men and women.

Another example is immunotherapy, which is a type of treatment that boosts the body’s own immune system to fight cancer. Some immunotherapy drugs, such as pembrolizumab or nivolumab, target a protein called programmed death-ligand 1 (PD-L1) that is expressed by some lung cancer cells to evade the immune system. These drugs have been shown to improve survival in some patients with advanced NSCLC, especially those with high levels of PD-L1 expression. However, some studies have suggested that men may have higher levels of PD-L1 expression than women and may respond better to these drugs.

Conclusion

Lung cancer is a complex and heterogeneous disease that affects men and women differently. There are differences in the incidence, risk factors, types, stages, survival rates, and treatment outcomes of lung cancer between genders. These differences may be influenced by biological, environmental, or social factors. Understanding these differences may help improve the prevention, diagnosis, and treatment of lung cancer for both men and women.

Bibliography

Eldridge L. Lung Cancer in Men vs. Women. Verywell Health. https://www.verywellhealth.com/gender-and-lung-cancer-2249406 (accessed Jan 11, 2024).

Lung Cancer Survival Rates: By Stage, Age, Type, and More. Healthline. https://www.healthline.com/health/lung-cancer-stages-survival-rates (accessed Jan 11, 2024).

Study: Young Women Now Have Higher Rates for Lung Cancer Than Men Worldwide. American Cancer Society. https://www.cancer.org/research/acs-research-news/study-young-women-now-have-higher-rate-for-lung-cancer-than-men-worldwide.html (accessed Jan 11, 2024).

Kaur S and Singh R. Genome-Wide Sex and Gender Differences in Cancer. Front Oncol 2020;10:597788.

Lung Cancer – Non-Small Cell: Stages | Cancer.Net. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/stages (accessed Jan 11, 2024).

Lung Cancer – Small Cell: Stages | Cancer.Net. https://www.cancer.net/cancer-types/lung-cancer-small-cell/stages (accessed Jan 11, 2024).

Order | Check Discount

Tags: Lung cancer treatment and success rates differ between genders